Vaccine used for infection prevention of toxoplasma gondii, preparation method and application of vaccine

Abstract

The invention firstly provides a nucleotide sequence used for infection prevention of toxoplasma gondii. The nucleotide sequence is selected from nucleotide sequences as follows: 1), a nucleotide sequence represented in a sequence table SEQIDNo.1; 2), a nucleotide sequence which is complementary with the nucleotide sequence represented in 1); and 3), a nucleotide sequence which performs substitution, loss and adding modification on one or more basic groups of the nucleotide sequence represented in 1) or 2) and has a toxoplasma gondii infection prevention function. The invention further provides a vaccine which comprises the nucleotide sequence and a medically acceptable carrier. The plasmid DNA vaccine pVAX-HSP60 can effectively prevent and control infection of a toxoplasma gondii animal model (a Kunming strain mouse), that is, the survival time of the mouse can be effectively prolonged, and worm count of brain cyst is reduced, so that the plasmid pVAX-HSP60 can be used as a DNA vaccine candidate antigen for resisting infection of toxoplasma gondii.

Description

technical field [0001] The invention belongs to the fields of immunology and molecular biology, and in particular relates to a vaccine for preventing toxoplasma gondii infection. Background technique [0002] Toxoplasma gondii (Toxoplasma gondii) is a worldwide distribution of obligate intracellular parasitic protozoa, with a very wide range of hosts, can infect almost all warm-blooded animals including humans. The pathogen can infect the host through congenital or acquired routes, and most of the infections are recessive infections without obvious clinical symptoms; major cause of death. [0003] Among human infected groups, pregnant women have a higher incidence and are more harmful. Toxoplasma gondii can be vertically transmitted to the fetus through the placental barrier, often causing premature birth, miscarriage, teratosis, stillbirth and other adverse symptoms, and the surviving fetuses are often accompanied by congenital diseases, such as: mental retardation, toxop...

AI Technical Summary

Problems solved by technology

The research on the immune protection of these vaccine candidate antigens shows that they are all immunogenic and can induce cellular and humoral immune responses to resist the challenge infection of Toxoplasma gondii. They have certain immune protection, but they have not reached Desired full protective effect

The reason is that because Toxoplasma gondii has a complex life cycle, various forms, and a wide range of hosts, the immunogens of different antigens are also different, and the pathogenic mechanisms of its cysts and tachyzoites are also different. Candidate antigens for vaccines based on a single antigenic component, but because they contain few lymphocyte binding sites and the receptor's major histocompatibility complex (Major histocompatibility complex, MHC) is highly restrictive, it is difficult to form effective resistance Fighting against different forms of Toxoplasma gondii attack infection

Therefore, it is difficult to achieve the desired effect only by relying on these few candidate antigen genes, and to find more and better DNA vaccine candidate antigens derived from different stages of Toxoplasma gondii, especially the antigen genes related to the virulence of Toxoplasma gondii. An important way to study vaccines against Toxoplasma gondii

Images